Person who experienced the adverse event (patient)
| Event ID | CASEID | CASEVERSION | I F COD | EVENT DT | MFR DT | INIT FDA DT | FDA DT | REPT COD | AUTH NUM | MFR NUM | MFR SNDR | LIT REF | AGE | AGE COD | AGE GRP | GNDR COD | E SUB | WT | WT COD | REPT DT | TO MFR | OCCP COD | REPORTER COUNTRY | OCCR COUNTRY |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 126403081 | 12640308 | 1 | I | 201006 | 20111201 | 20160810 | 20160810 | EXP | US-VALIDUS PHARMACEUTICALS LLC-US-2011VAL000419 | VALIDUS | 0.00 | Y | 0.00000 | 20160810 | CN | US | US |
Drug(s) used by person
| Event ID | CASEID | DRUG SEQ | ROLE COD | DRUGNAME | PROD AI | VAL VBM | ROUTE | DOSE VBM | CUM DOSE CHR | CUM DOSE UNIT | DECHAL | RECHAL | LOT NUM | EXP DT | NDA NUM | DOSE AMT | DOSE UNIT | DOSE FORM | DOSE FREQ |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 126403081 | 12640308 | 1 | PS | CALCITRIOL. | CALCITRIOL | 1 | Subcutaneous | 0.2 ?G, 1 IN 1 D | U | 18044 | .2 | UG | CAPSULE | ||||||
| 126403081 | 12640308 | 2 | SS | CALCITRIOL. | CALCITRIOL | 1 | Oral | 0.2 ?G, 1 IN 1 D | U | 18044 | .2 | UG | CAPSULE | ||||||
| 126403081 | 12640308 | 3 | SS | CALCITRIOL. | CALCITRIOL | 1 | U | 18044 | CAPSULE | ||||||||||
| 126403081 | 12640308 | 4 | C | NEPHRONEX | 2 | Oral | 1 ML, 1 IN 1 D | U | 0 | 1 | ML | ||||||||
| 126403081 | 12640308 | 5 | C | NEPHRONEX | 2 | Oral | 0.5 ML, 1 IN 1 D | U | 0 | .5 | ML | ||||||||
| 126403081 | 12640308 | 6 | C | FERROUS SULFATE. | FERROUS SULFATE | 1 | Oral | FORM STREGTH: 15 MG/ML (2 ML,2 IN 1 D) | U | 0 | 2 | ML | |||||||
| 126403081 | 12640308 | 7 | C | SODIUM BICARBONATE. | SODIUM BICARBONATE | 1 | Oral | 9 MEQ, 2 IN 1 D | U | 0 | 9 | MEQ | |||||||
| 126403081 | 12640308 | 8 | C | CALCIUM CARBONATE. | CALCIUM CARBONATE | 1 | Oral | FORM STRENGTH: 100MG/ML (2 ML,3 IN 1 D) | U | 0 | 2 | ML | |||||||
| 126403081 | 12640308 | 9 | C | PERIACTIN | CYPROHEPTADINE HYDROCHLORIDE | 1 | Oral | FORM STRENGHT: 2 MG/5ML (0.8 ML,2 IN 1 D) | 0 | .8 | ML |
Indications of drugs used
| Event ID | CASEID | INDI DRUG SEQ | INDI PT |
|---|---|---|---|
| 126403081 | 12640308 | 1 | Chronic kidney disease |
| 126403081 | 12640308 | 2 | Bone disorder |
| 126403081 | 12640308 | 3 | Mineral metabolism disorder |
| 126403081 | 12640308 | 4 | Product used for unknown indication |
| 126403081 | 12640308 | 6 | Product used for unknown indication |
| 126403081 | 12640308 | 7 | Product used for unknown indication |
| 126403081 | 12640308 | 8 | Product used for unknown indication |
| 126403081 | 12640308 | 9 | Product used for unknown indication |
Outcome of event
| Event ID | CASEID | OUTC COD |
|---|---|---|
| 126403081 | 12640308 | HO |
Reactions reported
| Event ID | CASEID | DRUG REC ACT | PT |
|---|---|---|---|
| 126403081 | 12640308 | Failure to thrive | |
| 126403081 | 12640308 | Urinary tract infection | |
| 126403081 | 12640308 | Vomiting |
Reporting Sources (this data is often not reported and may therefore be missing here)
| no results found |
Therapies reported
| Event ID | CASEID | DSG DRUG SEQ | START DT | END DT | DUR | DUR COD |
|---|---|---|---|---|---|---|
| 126403081 | 12640308 | 4 | 20110725 | 0 | ||
| 126403081 | 12640308 | 5 | 20110725 | 0 | ||
| 126403081 | 12640308 | 9 | 20110725 | 0 |